Literature DB >> 12829725

Topical capsaicin-induced allodynia in unanesthetized primates: pharmacological modulation.

Eduardo R Butelman1, Jonathan W Ball, Todd J Harris, Mary Jeanne Kreek.   

Abstract

Topically administered capsaicin produces thermal allodynia, and this effect has been used to investigate pain transduction and its pharmacological modulation. This study investigated the parameters of topical capsaicin-induced thermal allodynia in unanesthetized rhesus monkeys and its pharmacological modulation by centrally acting compounds [a kappa-opioid agonist: (5alpha,7alpha,8beta)-(+)-N-methyl-N-(7-[1-pyrrolidinyl]-1-oxaspiro [4.5]dec-8-yl)-benzeneacetamide (U69,593); and noncompetitive N-methyl-d-aspartate (NMDA) antagonists: ketamine and MK-801 (dizocilpine)]. Rhesus monkeys (n = 4) were studied within the warm water tail withdrawal assay (20-s maximum latency), using thermal stimuli that are normally not noxious (38 and 42 degrees C). Capsaicin was applied topically on the tail (0.0013 and 0.004 M capsaicin solution on a 1-cm2 patch; 15-min contact). Topical capsaicin produced concentration-dependent thermal allodynia in both temperatures, robustly detected 15 to 90 min after topical capsaicin removal. A similar allodynic profile was observed with topical administration of the "endovanilloid" N-arachidonoyl-dopamine. The kappa-agonist U69,593 (0.01-0.1 mg/kg, s.c.) dose dependently prevented capsaicin (0.004 M)-induced allodynia in 38 and 42 degrees C, and the largest U69,593 dose also reversed ongoing allodynia within this model. Two NMDA antagonists, ketamine and MK-801 (0.32-1.8 and 0.032-0.056 mg/kg, respectively), also prevented capsaicin-induced allodynia in 38 degrees C, but only variably in 42 degrees C, at doses that did not cause robust thermal antinociceptive effects. At the largest doses studied, ketamine but not MK-801 also briefly reversed ongoing capsaicin-induced allodynia. The present model of topical capsaicin administration may be used to study antiallodynic effects of opioid and nonopioid compounds, as well as their ability to prevent and reverse allodynia, in unanesthetized nonhuman primates in the absence of tissue disruption.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829725     DOI: 10.1124/jpet.103.052381

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

Review 1.  N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets.

Authors:  Mark Connor; Chris W Vaughan; Robert J Vandenberg
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Selective enhancement of fentanyl-induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus monkeys: Further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics.

Authors:  Matthew L Banks; John E Folk; Kenner C Rice; S Stevens Negus
Journal:  Pharmacol Biochem Behav       Date:  2010-08-03       Impact factor: 3.533

Review 3.  The expanding field of cannabimimetic and related lipid mediators.

Authors:  Heather B Bradshaw; J Michael Walker
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

4.  Additive and subadditive antiallodynic interactions between μ-opioid agonists and N-methyl D-aspartate antagonists in male rhesus monkeys.

Authors:  Jeremy C Cornelissen; Floyd F Steele; Kenner C Rice; Katherine L Nicholson; Matthew L Banks
Journal:  Behav Pharmacol       Date:  2018-02       Impact factor: 2.293

5.  Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates.

Authors:  Mei-Chuan Ko; Stephen M Husbands
Journal:  Handb Exp Pharmacol       Date:  2020-12-04

6.  Differential effects of opioid-related ligands and NSAIDs in nonhuman primate models of acute and inflammatory pain.

Authors:  Devki D Sukhtankar; Heeseung Lee; Kenner C Rice; Mei-Chuan Ko
Journal:  Psychopharmacology (Berl)       Date:  2013-11-12       Impact factor: 4.530

7.  Microsomal omega-hydroxylated metabolites of N-arachidonoyl dopamine are active at recombinant human TRPV1 receptors.

Authors:  N Rimmerman; H B Bradshaw; A Basnet; B Tan; Theodore S Widlanski; J M Walker
Journal:  Prostaglandins Other Lipid Mediat       Date:  2008-09-02       Impact factor: 3.072

8.  Inhibitory effect of N-Acyl dopamines on IgE-mediated allergic response in RBL-2H3 cells.

Authors:  Jae-Myung Yoo; Eun Seok Park; Mee Ree Kim; Dai-Eun Sok
Journal:  Lipids       Date:  2013-02-02       Impact factor: 1.880

9.  Behavioral pharmacology of the mu/delta opioid glycopeptide MMP2200 in rhesus monkeys.

Authors:  Gail Pereira Do Carmo; Robin Polt; Edward J Bilsky; Kenner C Rice; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2008-05-29       Impact factor: 4.030

Review 10.  Translational value of non-human primates in opioid research.

Authors:  Huiping Ding; Mei-Chuan Ko
Journal:  Exp Neurol       Date:  2021-01-14       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.